Compare Oklo Inc (OKLO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oklo Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Oklo Inc trades at $35.24 (market cap $6.85B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.7× Oklo Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oklo Inc for 31 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| OKLO | VRTX | |
|---|---|---|
Market Cap | $6.85B | $128.16B |
Volume | 11,387,867 | 806,603 |
Sector | Utilities | Health |
52-Week High | $174.14 | $557.96 |
52-Week Low | $34.57 | $407.37 |
Typical Hold Time | 31 Days | 120 Days |
Enterprise Value | $4.39B | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKLO trades at $36.82, down 4.49% on the day, with bearish technical indicators showing resistance at $37-38. The company shows no revenue in 2025 and negative net income of -$105.66M, though analyst consensus remains strongly bullish with a $78.63 price target. Recent news highlights nuclear energy sector momentum but notes OKLO's early commercialization stage and recent $1 billion stock sale.
Outlook hinges on project pipeline execution amid substantial cash burn. High institutional support via financing ($1.26B in 2025) fuels growth bets, but profitability remains distant with a -12,625.54% net margin. Risks include dilution from equity raises and intense SMR competition. The stock offers speculative upside if contracts materialize but carries high volatility.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
